Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1593

1.

Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.

Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group.

Ann Intern Med. 2009 Oct 20;151(8):517-27.

PMID:
19841453
2.

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.

Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.

Ann Intern Med. 2007 Apr 17;146(8):545-55. Epub 2007 Feb 19.

PMID:
17310045
3.

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.

Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P; TRISTSAN study group.

Thorax. 2005 Apr;60(4):301-4.

4.

A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.

Donohue JF, Kalberg C, Emmett A, Merchant K, Knobil K.

Treat Respir Med. 2004;3(3):173-81.

PMID:
15219176
5.

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.

Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC; COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group.

Thorax. 2005 Jun;60(6):480-7.

6.

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.

Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK; SCO30005 Study Group.

Am J Respir Crit Care Med. 2006 Apr 1;173(7):736-43. Epub 2006 Jan 19.

PMID:
16424444
7.

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators.

N Engl J Med. 2007 Feb 22;356(8):775-89.

8.

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.

Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM.

Am J Respir Crit Care Med. 2008 Aug 15;178(4):332-8. doi: 10.1164/rccm.200712-1869OC. Epub 2008 May 29.

PMID:
18511702
9.

Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.

Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y.

Respirology. 2009 Mar;14(2):239-44. doi: 10.1111/j.1440-1843.2008.01452.x. Epub 2008 Dec 11.

PMID:
19210650
11.

[Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].

Fang LZ, Liang X, Zhang JQ, Liu L, Fu WP, Zhao ZH, Dai LM.

Zhonghua Jie He He Hu Xi Za Zhi. 2008 Nov;31(11):811-4. Chinese.

PMID:
19080533
12.

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.

Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.

Respir Med. 2008 Aug;102(8):1099-108. doi: 10.1016/j.rmed.2008.04.019. Epub 2008 Jul 9.

13.

[Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].

Baloira Villar A, Vilariño Pombo C.

Arch Bronconeumol. 2005 Mar;41(3):130-4. Spanish.

14.

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes.

Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O'Dell D, Kalberg C, Crater G.

COPD. 2009 Oct;6(5):320-9.

PMID:
19863361
16.

Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease.

Lyseng-Williamson KA, Keating GM.

Am J Respir Med. 2002;1(4):273-82; discussion 283-4. Review.

PMID:
14720047
17.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.

Clin Ther. 2012 Aug;34(8):1655-66.e5. doi: 10.1016/j.clinthera.2012.06.005. Epub 2012 Jul 11.

PMID:
22789766
18.

Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma.

Koopmans JG, Lutter R, Jansen HM, van der Zee JS.

Thorax. 2006 Apr;61(4):306-12. Epub 2006 Jan 31.

20.

Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma.

Wallin A, Sue-Chu M, Bjermer L, Ward J, Sandström T, Lindberg A, Lundbäck B, Djukanović R, Holgate S, Wilson S.

J Allergy Clin Immunol. 2003 Jul;112(1):72-8.

PMID:
12847482

Supplemental Content

Support Center